TIMP1 and ovarian carcinoma: Ovarian cancer patients are often treated with antracyclines in the case of platinum resistant relapse and it may therefore be of interest to investigate whether positive TIMP-1 immunoreactivity would be associated with resistance to antracycline treatment in platinum resistant ovarian cancer patients.